A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis

Paul N. NewtonHung Thai LeQuoc Tip NguyenJennifer M. ShortWirongrong ChierakulAdul RajanuwongPunnee PitisuttithumSanchai ChasombatBenjaluck PhonratWirach Maek-A-NantawatReungsilp TeaunadiDavid G. LallooNicholas J. WhiteMahidol UniversitySappasitthiprasong HospitalNorth East Regional Infectious Disease HospitalJohn Radcliffe HospitalLiverpool School of Tropical MedicineInstitute of Malariology, Parasitology and Entomology2018-07-242018-07-242002-09-15Clinical Infectious Diseases. Vol.35, No.6 (2002), 769-772105848382-s2.0-0037105698https://repository.li.mahidol.ac.th/handle/123456789/20358We conducted a trial of oral acetazolamide for the treatment of cryptococcal meningitis in 22 Thai adults with headache and an opening cerebrospinal fluid pressure of ≥200 mm H2O. The trial was terminated prematurely because patients who received acetazolamide developed significantly lower venous bicarbonate levels and higher chloride levels and had more-frequent serious adverse events than did subjects who received placebo.Mahidol UniversityMedicineA randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitisArticleSCOPUS10.1086/342299